Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples

Markus Riester, Wei Wei, Levi Waldron, Aedin C. Culhane, Lorenzo Trippa, Esther Oliva, Sung Hoon Kim, Franziska Michor, Curtis Huttenhower, Giovanni Parmigiani, Michael J. Birrer

Research output: Contribution to journalArticle

Abstract

Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P

Original languageEnglish (US)
Article numberdju048
JournalJournal of the National Cancer Institute
Volume106
Issue number5
DOIs
StatePublished - May 14 2014
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Meta-Analysis
Reverse Transcription
Survival
Polymerase Chain Reaction
Transcriptome
Immunohistochemistry
Confidence Intervals
Genes
Datasets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., ... Birrer, M. J. (2014). Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute, 106(5), [dju048]. https://doi.org/10.1093/jnci/dju048

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. / Riester, Markus; Wei, Wei; Waldron, Levi; Culhane, Aedin C.; Trippa, Lorenzo; Oliva, Esther; Kim, Sung Hoon; Michor, Franziska; Huttenhower, Curtis; Parmigiani, Giovanni; Birrer, Michael J.

In: Journal of the National Cancer Institute, Vol. 106, No. 5, dju048, 14.05.2014.

Research output: Contribution to journalArticle

Riester, M, Wei, W, Waldron, L, Culhane, AC, Trippa, L, Oliva, E, Kim, SH, Michor, F, Huttenhower, C, Parmigiani, G & Birrer, MJ 2014, 'Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples', Journal of the National Cancer Institute, vol. 106, no. 5, dju048. https://doi.org/10.1093/jnci/dju048
Riester, Markus ; Wei, Wei ; Waldron, Levi ; Culhane, Aedin C. ; Trippa, Lorenzo ; Oliva, Esther ; Kim, Sung Hoon ; Michor, Franziska ; Huttenhower, Curtis ; Parmigiani, Giovanni ; Birrer, Michael J. / Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. In: Journal of the National Cancer Institute. 2014 ; Vol. 106, No. 5.
@article{dcd37704314e4925be20d6baa267de79,
title = "Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples",
abstract = "Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95{\%} confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P",
author = "Markus Riester and Wei Wei and Levi Waldron and Culhane, {Aedin C.} and Lorenzo Trippa and Esther Oliva and Kim, {Sung Hoon} and Franziska Michor and Curtis Huttenhower and Giovanni Parmigiani and Birrer, {Michael J.}",
year = "2014",
month = "5",
day = "14",
doi = "10.1093/jnci/dju048",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples

AU - Riester, Markus

AU - Wei, Wei

AU - Waldron, Levi

AU - Culhane, Aedin C.

AU - Trippa, Lorenzo

AU - Oliva, Esther

AU - Kim, Sung Hoon

AU - Michor, Franziska

AU - Huttenhower, Curtis

AU - Parmigiani, Giovanni

AU - Birrer, Michael J.

PY - 2014/5/14

Y1 - 2014/5/14

N2 - Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P

AB - Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P

UR - http://www.scopus.com/inward/record.url?scp=84902460514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902460514&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju048

DO - 10.1093/jnci/dju048

M3 - Article

C2 - 24700803

AN - SCOPUS:84902460514

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

M1 - dju048

ER -